Introduction The treatment algorithm of advanced hepatocellular carcinoma (HCC) has
evolved since the introduction of immunotherapy. The IMbrave150 trial set atezolizumab …

Graphene is a one-atom-thick carbon compound, which holds promises for detecting cancer
biomarkers along with its derivatives. The atom-wide graphene layer is ideal for cancer …

Bone and soft tissue sarcomas account for approximately 15% of pediatric solid malignant
tumors and 1% of adult solid malignant tumors. There are over 50 subtypes of sarcomas …

Chimeric antigen receptor (CAR) T therapy represents a form of immune cellular therapy
with clinical efficacy and a specific target. A typical chimeric antigen receptor (CAR) …

Angiogenesis is a crucial process for tissue development, repair, and tumor survival.
Vascular endothelial growth factor (VEGF) is a key driver secreted by cancer cells …

The involvement of cardiovascular disease in cancer onset and development represents a
contemporary interest in basic science. It has been recognized, from the most recent …

Non-alcoholic fatty liver disease (NAFLD) is emerging as an epidemic risk factor for
hepatocellular carcinoma (HCC). The progression of NAFLD to HCC is closely associated …

Colorectal cancer (CRC) is one of the deadliest cancers in the world, the incidences and
morality rate are rising and poses an important threat to the public health. It is known that …

Vascular endothelial growth factor A (VEGF-A or VEGF) is a highly conserved secreted
signalling protein best known for its roles in vascular development and angiogenesis. Many …

This review explores the dynamic landscape of hepatocellular carcinoma (HCC) treatment,
emphasizing on recent developments across various stages and therapeutic approaches …